Dave (DAVE) Lost Appeal as Valuation Became Too Expensive

Reported by Yahoo Finance · Published 28 Jul 2026, 8:17 PM MYT (2 hr ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

I got an unexpected $1,000 medical bill. Here’s why I’m not paying it yet. 1 hr ago Apple tops $5 trillion market cap, only second company to hit the milestone 1 hr ago Las Vegas home prices post largest drop in the nation 1 hr ago Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls 1 hr ago Should You Buy Altria for Its 5.8% Dividend Yield Ahead of July 30 Earnings? 1 hr ago AstraZeneca's drug pipeine is splitting opinion among City analysts 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Dave (DAVE) Lost Appeal as Valuation Became Too Expensive

Summary

More in Markets

I got an unexpected $1,000 medical bill. Here’s why I’m not paying it yet.

Apple tops $5 trillion market cap, only second company to hit the milestone

Las Vegas home prices post largest drop in the nation

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

Should You Buy Altria for Its 5.8% Dividend Yield Ahead of July 30 Earnings?

AstraZeneca's drug pipeine is splitting opinion among City analysts